ArticleThoracic cancer2024

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.

Zhicheng Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.